We hypothesized that TE‐1146 is more effective in killing CD38+‐MM cells than the daratumumab/lenalidomide combination (Figure 6a–e), because it binds to CD38 and releases the lenalidomide inside the MM cells, whereas the daratumumab/lenalidomide combination lacks this intracellular action. This evidence concerns the gene CD38 and Miyoshi myopathy.